Details of the Drug

General Information of Drug (ID: DMG9VHN)

Drug Name
Depemokimab
Synonyms GSK3511294
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 3 [1]
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
DS9J7L

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-5 (IL5) TTPREZD IL5_HUMAN Antagonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Asthma
ICD Disease Classification CA23
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-5 (IL5) DTT IL5 6.51E-01 -0.02 -0.11
Interleukin-5 (IL5) DTT IL5 1.71E-04 0.12 0.71
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04719832) A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype. U.S.National Institutes of Health.
2 A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. Br J Clin Pharmacol. 2022 Feb;88(2):702-712.